Welcome to our dedicated page for Esperion Therapeutics news (Ticker: $ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Esperion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Esperion Therapeutics's position in the market.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) to report Q4 and full year 2023 financial results on February 27, 2024. Webcast to discuss financial results and business updates. Esperion focuses on innovative medicines for cardiovascular and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
-
Rhea-AI Summary
RFK Racing and Esperion Therapeutics have announced a promotional schedule for the 2024 season, featuring a four-race slate highlighting NEXLIZET and NEXLETOL, used to reduce LDL-cholesterol. The season debut comes in the first race at Richmond this spring, with additional races at North Wilkesboro, Pocono, and Talladega. The partnership between RFK and Esperion will promote a myriad of campaigns and initiatives, including National Wear Red Day, American Heart Month, Stress Awareness Month, Women’s Health Awareness Month, Men’s Health Awareness Month, a Wellness Walk, Cholesterol Education Month, World Heart Day, National Health Education Week, and Family Health History Day. NEXLIZET should not be used in patients who have had a previous allergic reaction to ezetimibe. NEXLIZET and NEXLETOL can increase levels of uric acid in the blood which can lead to gout. Esperion's CEO expressed excitement about the robust marketing campaign and the race schedule, highlighting the combined efforts on promoting cholesterol awareness and various additional health awareness months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
-
Rhea-AI Summary
Esperion Therapeutics, Inc. announced the closing of its underwritten public offering of 65,205,000 shares of its common stock, raising approximately $97.8 million. The company plans to use the net proceeds for ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
Rhea-AI Summary
Esperion Therapeutics, Inc. announced the pricing of its underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of approximately $85.1 million. The offering is expected to close on January 23, 2024, and the net proceeds will fund ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
-
Rhea-AI Summary
Esperion Therapeutics, Inc. has announced the commencement of an underwritten public offering of shares of its common stock, with the underwriters granted a 30-day option to purchase additional shares. The company plans to use the net proceeds to fund ongoing commercialization efforts, research and clinical development, working capital, capital expenditures, and general corporate purposes. The offering is subject to market conditions and the actual size or terms are uncertain. Jefferies LLC is acting as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
-
Rhea-AI Summary
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) announced a $125 million amendment to their collaboration, including a $100 million payment to Esperion and expansion of collaboration in Europe and other territories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.23%
Tags
Rhea-AI Summary
Esperion (NASDAQ: ESPR) is participating in the 42nd Annual J.P. Morgan Healthcare Conference. President and CEO Sheldon Koenig will deliver a corporate presentation on January 10, 2024, at 2:15 PM PT. Esperion focuses on discovering, developing, and commercializing innovative medicines for cardiovascular and cardiometabolic diseases. The company aims to improve outcomes for patients with high cholesterol, providing the next steps to help get patients to their LDL-cholesterol level goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.93%
Tags
-
Rhea-AI Summary
Esperion (NASDAQ: ESPR) receives FDA approval for updated label indications for NEXLETOL and NEXLIZET, removing the maximally tolerated statin requirement and limitation of use for primary hyperlipidemia. The approval reinforces the proven efficacy and safety of these treatments. The label updates do not impact the pending approvals for cardiovascular risk reduction indications. The PDUFA date for these approvals is March 31, 2024, and anticipated approval in Europe is in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.57%
Tags
-
Rhea-AI Summary
Esperion (NASDAQ: ESPR) announced results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. The analysis highlighted the potential of bempedoic acid to reduce vascular inflammation, especially in statin-intolerant patients. Results showed a 21.6% reduction in the inflammatory marker hsCRP in patients taking bempedoic acid. Dr. Paul Ridker presented the analysis, emphasizing the importance of inflammation inhibition alongside cholesterol reduction in improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
Rhea-AI Summary
ESPR: Esperion to Participate in TRANSFORM Trial for Heart Disease Evaluation and Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Esperion Therapeutics, Inc.
Nasdaq:ESPR
ESPR Rankings
ESPR Stock Data
390.17M
183.65M
0.45%
39.06%
10.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
ANN ARBOR
About ESPR
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.